New hope for tough lymphoma: experimental drug TLN-254 enters human testing

NCT ID NCT06733441

Recruiting now Disease control Sponsor: Treeline Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 34 times

Summary

This early-stage trial tests an experimental drug called TLN-254 in about 50 adults with T-cell lymphoma that has returned or not responded to prior therapy. The main goal is to see if the drug can shrink tumors or make them disappear. Researchers will also monitor side effects and measure drug levels in the blood.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

British Columbia Cancer Agency
RECRUITING

Vancouver, British Columbia, Canada

Contact Phone: •••-•••-•••• Email: •••••@•••••
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Sarah Cannon Research Institute
RECRUITING

Nashville, Tennessee, 37203, United States

Contact Phone: •••-•••-••••
Stanford Cancer Institute
RECRUITING

Stanford, California, 94305, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

LYMPHOMA